(LUCD) Lucid Diagnostics Inc. Business Model Canvas Research

Lucid Diagnostics Inc. depends on commercial insurers and Medicare coverage decisions, because reimbursement drives whether physicians order EsoGuard and whether patients can access it. The company must keep working with payers and Medicare contractors to secure payment for ordered diagnostics, since test volume rises only when coverage is clear and out-of-pocket cost is low.

• Coverage drives test adoption.
• Reimbursement supports payment.
• Payment affects volume and access.
• Doctors use it more when covered.

Lucid Diagnostics Inc. depends on manufacturing and supply chain vendors to produce EsoCheck hardware, its capsules, and related packaging and materials. Reliable suppliers matter because any disruption can slow device availability, delay commercial execution, and raise unit costs.

• Supports device production and packaging
• Secures sourcing for key materials
• Protects supply continuity for sales rollout

Lucid Diagnostics sells its EsoGuard test to providers who treat GERD, and sales plus medical affairs drive awareness and ordering. This is a screening market, not an emergency one, so education has to turn eligible clinicians into repeat users; GERD affects about 20% of U.S. adults.

• Target GI and primary care providers
• Support test ordering behavior
• Explain screening, not acute care
• Grow repeat use through education

Lucid Diagnostics must receive each sample, run the lab workflow, and return a clear result fast, because turnaround time is part of the product. In diagnostics, reliable reporting drives physician trust and repeat use, so delays can hurt adoption.

For Lucid Diagnostics, this activity centers on sample handling, assay processing, quality control, and on-time report delivery to clinicians.

• Receive and log patient samples
• Process assays with quality checks
• Return results on time
• Support physician confidence

Lucid Diagnostics Inc.'s commercial organization is a key resource because sales, medical affairs, and reimbursement teams drive physician adoption and payer access, which is what turns EsoGuard and related testing into revenue. These functions matter most in a market where Medicare and commercial coverage decisions can shape real-world test volume fast.

• Sales opens provider adoption

• Medical affairs supports clinical trust

• Reimbursement unlocks payer access

As a PAVmed subsidiary, Lucid Diagnostics can tap parent capital, governance, and shared admin support, which lowers overhead for a commercial-stage medtech company. That backing helps Lucid focus cash on test sales, reimbursement, and lab operations instead of building every corporate function alone.

• Parent capital support
• Shared governance oversight
• Lower admin overhead
• More cash for commercialization

Lucid Diagnostics Inc.’s office-based workflow lets sample collection happen in routine gastroenterology visits, so patients do not need an endoscopy suite for every test. That keeps the process closer to standard practice flow and can support broader adoption in high-volume GI offices.

In 2025, Lucid Diagnostics Inc. continued to position its non-endoscopic approach around easier access, faster throughput, and lower friction for screening pathways versus hospital-based procedures.

• Routine-office sample collection
• Less endoscopy-suite dependence
• Fits GI practice workflows

Lucid Diagnostics’ value proposition is the linked device-and-assay stack: the EsoCheck collection device and the EsoGuard DNA test work together to streamline Barrett’s esophagus screening for providers. This paired workflow reduces handoffs and supports a more differentiated, end-to-end diagnostic offer.

• Device plus molecular test, one workflow
• Helps simplify provider diagnostics
• Creates a distinct product stack

Lucid Diagnostics Inc. supports providers with billing and coverage guidance, which helps reduce friction after the first order. In 2025, that reimbursement help stayed central to repeat use because providers are more likely to reorder when they can bill with less uncertainty.

• Billing help lowers ordering friction
• Coverage guidance supports adoption
• Repeat orders depend on reimbursement

Test results are Lucid Diagnostics Inc.'s key relationship touchpoint: fast, clear reporting helps physicians act on findings and keeps the workflow sticky. In 2025, the company’s focus stayed on high-touch, clinician-facing service for EsoGuard and EsoCheck users, since diagnostic adoption depends on quick turnaround and easy-to-read results.

• Fast results support treatment decisions.
• Clear reporting improves physician trust.
• Operational follow-up helps retain users.

Lucid Diagnostics Inc. depends on electronic ordering and digital result delivery so providers can place, track, and receive tests without paper delays. That cuts staff touchpoints and helps keep lab workflow moving faster, which matters when turnaround time drives use.

• Electronic orders reduce manual errors
• Digital results speed provider follow-up
• Workflow tools ease lab bottlenecks

Large health systems and IDNs can standardize Lucid Diagnostics Inc. use across many clinicians, so one institutional sale can drive repeat EsoGuard volume. In 2025, Lucid said health-system outreach is a core growth path, and this channel matters because IDNs can speed protocol adoption across multi-site care networks.

• Centralizes clinician adoption
• Scales repeat test volume
• Fits multi-site IDN protocols

Primary care physicians are a key entry point for Lucid Diagnostics Inc. because they manage chronic reflux before specialist referral and can spot patients who meet Barrett’s esophagus screening criteria. In the U.S., GERD affects about 20% of adults, so PCP awareness can move more at-risk patients into earlier testing with EsoGuard and EsoCheck.

• Manage reflux first
• Screen high-risk patients earlier
• Drive specialist referrals

Health systems and payers are key gatekeepers for Lucid Diagnostics Inc. because they shape access, prior authorization, and reimbursement for large patient pools, including about 67 million Medicare beneficiaries. They care about clear clinical use and lower downstream cost, so their coverage calls can speed or slow market scale.

• They control access and reimbursement.
• They favor proven, appropriate use.
• They weigh downstream cost savings.

Lucid Diagnostics Inc.’s laboratory and manufacturing operations are driven by sample processing, device production, and supply chain support, so costs rise with test volume. Quality systems also keep the base cost heavy; in FY2025, that mix means more throughput can help spread fixed lab and compliance spend, but each test still carries material variable cost.

• Sample processing scales with volume
• Device production adds direct cost
• Supply chain support stays essential
• Quality systems lift fixed overhead

As a public Company, Lucid Diagnostics Inc. pays SEC, audit, board, and Nasdaq listing costs, and its G&A also covers finance, legal, HR, and headquarters staff. In the latest reported year, this overhead stayed a key fixed cost, because these functions keep day-to-day operations and reporting on track.

• Public-company reporting and governance costs
• Finance, legal, HR, and HQ support

Lucid Diagnostics Inc. relies on insurance and Medicare reimbursement for most clinical-diagnostic sales, so realized revenue depends on whether payers cover the test. In 2025, payer acceptance and Medicare coverage decisions remained the key gatekeepers for volume and cash collection.

• Third-party payers drive monetization
• Coverage decisions set realized revenue
• Medicare acceptance is critical

Without payer approval, billed tests can take longer to convert into cash, which makes reimbursement policy central to this stream.

Revenue grows when more practices and health systems adopt Lucid Diagnostics Inc.'s EsoGuard test, because each new site lifts ordered-test volume and related product use. Commercial scale still hinges on utilization growth per provider, not just new logos, since higher patient throughput is what converts adoption into repeat revenue.

• More sites drive more orders
• Throughput lifts recurring use
• Utilization is the main scale lever